Background {#Sec1}
==========

Uterine corpus endometrial cancer (UCEC) imposes a global burden in both developed and developing countries \[[@CR1]\]. In the United States, it is the most common gynecologic malignancy, accounting for 61,380 new cases in 2017 \[[@CR2]\]. In Korea, the incidence of UCEC is clearly increasing and is estimated to comprise 2.5% (2578) of all new female cancers in 2017 \[[@CR3], [@CR4]\].

In 2013, The Cancer Genome Atlas (TCGA) Research Network issued an integrated report of genomic, transcriptomic, and proteomic profiles in 373 patients diagnosed with UCEC \[[@CR5]\]. Furthermore, this consortium determined four prognostic categories (good→poor as shown) for classification of UCEC: (1) polymerase ɛ (POLE) ultramutated; (2) microsatellite instability (MSI) hypermutated; (3) low copy number; and (4) high copy number. The high copy number group in particular includes most of the serous and serous-like endometrioid tumors, sharing genomic features with ovarian serous carcinomas. Researchers have since incorporated these molecular criteria into clinical trials designed to gauge postsurgical adjuvant treatment of UCEC (10.1186/ISRCTN11659025).

In keeping with the era of precision medicine, discovery of reliable genetic changes is essential to provide individualized treatment of patients with UCEC \[[@CR5], [@CR6]\]. Little-known genes such as *LYL1* may now be identified as novel prognostic indicators or as potential therapeutic targets. The *LYL1* gene is located on the short (p) arm of chromosome 19 at position 13.13, where it encodes a protein implicated in blood vessel maturation and haematopoiesis \[[@CR7]\]. As a member of basic helix-loop-helix transcription factor family, the *LYL1* gene is also known to regulate cell proliferation and differentiation \[[@CR8]\], and a form of T-cell acute lymphoblastic leukaemia has been linked to a chromosomal aberration of *LYL1* \[[@CR7]\].

Curiously, somatic amplifications of the *LYL1* gene frequently accompany UCEC, more so than most other cancers, ranking second among TCGA listings. However, its ramifications in this setting have yet to be fully explored. The current study, entailing TCGA database analysis, was undertaken to determine whether genetic alterations in the *LYL1* gene (such as amplification) may impact survival outcomes in patients with UCEC.

Methods {#Sec2}
=======

Data acquisition {#Sec3}
----------------

We downloaded genomic alteration data on patients with UCEC and corresponding clinicopathologic profiles at the Genomics Data Commons (<https://portal.gdc.cancer.gov>) and cBioPortal for Cancer Genomics ([http://www.cbioportal.org](http://www.cbioportal.org/)) web portals. The Illumina Genome Analyzer served as platform for DNA sequencing (Illumina Inc., San Diego, CA, USA). This study complied with TCGA publication guidelines and policies (<http://cancergenome.nih.gov/publications/publicationguidelines>). The Institutional Review Board of Seoul National University Hospital ruled that no formal ethics approval was required in this study.

Study population {#Sec4}
----------------

In total, 370 patients with UCEC qualified for this study. The clinicopathologic data collected included age, underlying comorbidities, International Federation of Gynecology and Obstetrics (FIGO) stage, tumor histologic type and grade, and treatment of UCEC (ie, surgery, radiation, chemotherapy). Tumor MSI status was also collected. Patients were assigned to *LYL1* gene amplification and non-amplification groups as warranted.

Bioinformatics analysis {#Sec5}
-----------------------

*LYL1* gene status, especially whether it was amplified, was determined through the cBioPortal for Cancer Genomics ([http://www.cbioportal.org](http://www.cbioportal.org/)). Level-3 data of patients with UCEC and raw reads (HTSeq-counts) of differentially expressed gene (DEG) analyses were accessed via FireBrowse (<http://firebrowse.org>). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of gene expression data \[[@CR9]\] was subjected to Gene Set Enrichment Analysis (GSEA) \[[@CR10]\]. For visualization of enrichment pathway, the NetworkAnalyst (<http://www.networkanalyst.ca>) was used \[[@CR11]\].

In doing so, the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database was applied, achieving confidence scores of 400--1000 \[[@CR12]\]. DEGs were identified through open-source software analysis (R package DESeq2; <http://www.bioconductor.org>) \[[@CR13]\].

Statistical analysis {#Sec6}
--------------------

To compare clinicopathologic features of the two patient subsets, Student's *t*-test and Mann-Whitney *U*-test were applied to continuous variables, and Pearson's chi-squared and Fisher's exact tests for categorical variables.

We defined PFS as the time elapsed between date of initial diagnosis and date of disease progression, whereas overall survival (OS) represented the time interval between date of initial diagnosis and date of cancer-related death or end of study. Survival estimates were generated via Kaplan-Meier method and log-rank test. Cox proportional hazards regression models were engaged to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). For survival analytics, we relied on commercially available software (SPSS v21.0; IBM, Armonk, NY, USA). Open-source programming (R v2.12.1, ISBN 3--900,051--07-0, <http://www.R-project.org>; R Foundation for Statistical Computing, Vienna, Austria) was used for all other computations. Statistical significance was set at *P* \< 0.05.

Results {#Sec7}
=======

Somatic copy number variations in UCEC {#Sec8}
--------------------------------------

Frequencies of somatic amplifications involving the *LYL1* gene are depicted according to TCGA classification in Fig. [1a](#Fig1){ref-type="fig"}. UCEC ranked second among cancers in terms of *LYL1* gene amplification. In genomic alteration analyses, chromosomes 1q, 3q, 8q, 17q, and 19p were frequently amplified in this patient population (Fig. [1b](#Fig1){ref-type="fig"}). The *LYL1* gene of 19p arm was amplified in 5.9% (22/370) of patients with UCEC. Additionally, the *LYL1* gene was one of the 15 mostly amplified oncogenes filtered by gene family in GSEA (Fig. [1c](#Fig1){ref-type="fig"}). Meanwhile, the 15 mostly deleted tumor suppressor genes, including *PTEN*, are displayed in Fig. [1d](#Fig1){ref-type="fig"}.Fig. 1Analysis of gene amplification in various cancer types and uterine corpus endometrial carcinoma: **a** frequencies of copy number variations across chromosomes; **b** frequencies of *LYL1* gene amplification in various cancer types; **c** correlations between amplification frequencies and mortality across top 15 oncogenes; and (**d**) correlations between deletion frequencies and mortality across top 15 tumor suppressor genes in uterine corpus endometrial carcinoma

Characteristics of patients with UCEC {#Sec9}
-------------------------------------

Patients' clinicopathologic characteristics are presented in Table [1](#Tab1){ref-type="table"}. Mean patient age was 63 years. Of the 370 patient participants, 304 (82.2%), 52 (14.1%), and 14 (3.8%) displayed endometrioid, serous, and mixed histologic types of UCEC, respectively. Members of the *LYL1* amplification (vs. non-amplification) group were significantly older at time of diagnosis and more often exhibited biologically aggressive tumors, marked by advanced-stage disease (FIGO stage III-IV; *P* = 0.003), high-grade malignancy (grade 3; *P* \< 0.001), and serous histologic type (*P* \< 0.001). Proportions of the four TCGA categories of UCEC also showed comparative differences, with 72.7% of amplification group members achieving high copy number rank, versus 12.1% in the non-amplification group (*P* \< 0.001). In terms of adjuvant treatment, chemotherapy recipients were more numerous in *LYL1* amplification group than in non-amplification group (50.0% vs 28.4%; *P* = 0.032) (Table [1](#Tab1){ref-type="table"}).Table 1Clinicopathologic characteristics of patientsCharacteristicsAll (*n* = 370, %)*LYL1* amplification (*n* = 22, %)*LYL1* non-amplification (*n* = 348, %)*P*Age, years\< 0.001 Mean ± SD63.1 ± 11.072.7 ± 8.062.5 ± 10.9Menopause^a^0.393 Yes313 (84.6)0 (0)27 (7.8) No27 (7.3)21 (95.5)292 (83.9) Unknown30 (8.1)1 (4.5)29 (8.3)Diabetes0.774 Yes83 (22.4)5 (22.7)78 (22.4) No221 (59.7)11 (50.0)210 (60.3) Unknown66 (17.8)6 (27.3)60 (17.2)Hypertension0.420 Yes195 (52.7)11 (50.0)184 (52.9) No135 (36.5)5 (22.7)130 (37.4) Unknown40 (10.8)6 (27.3)34 (9.8)Histologic type\< 0.001 Endometrioid304 (82.2)6 (27.3)298 (85.6) Serous52 (14.1)13 (59.1)39 (11.2) Mixed14 (3.8)3 (13.6)11 (3.2)Grade\< 0.001 188 (23.8)0 (0)88 (25.3) 2106 (28.6)1 (4.5)105 (30.2) 3176 (47.6)21 (95.5)155 (44.5)FIGO stage0.003 I254 (68.6)9 (40.9)245 (70.4) II24 (6.5)2 (9.1)22 (6.3) III72 (19.5)9 (40.9)63 (18.1) IV17 (4.6)2 (9.1)15 (4.3) Unknown3 (0.8)0 (0)3 (0.9)TCGA type POLE ultra-mutated17 (4.6)0 (0)17 (4.9)0.612 MSI hyper-mutated65 (17.6)0 (0)65 (18.7)0.019 Low copy number90 (24.3)0 (0)90 (25.9)0.006 High copy-number58 (15.7)16 (72.7)42 (12.1)\< 0.001 Indeterminate140 (37.8)6 (27.3)134 (38.5)0.292MSI status\< 0.001 Stable223 (60.2)22 (100.0)201 (57.8) Low19 (5.1)0 (0)19 (5.5) High125 (33.7)0 (0)125 (35.9) Indeterminate3 (0.8)0 (0)3 (0.9)Adjuvant treatment Chemotherapy only110 (29.7)11 (50.0)99 (28.4)0.032 Radiation only55 (14.9)2 (9.1)53 (15.2)0.756 Chemotherapy + Radiation23 (6.2)1 (4.5)22 (6.3)1.000 Hormone therapy17 (4.6)0 (0)17 (4.9)0.612*Abbreviations*: *FIGO* International Federation of Gynecology and Obstetrics, *TCGA* The Cancer Genome Atlas; *POLE* polymerase ɛ, *MSI* microsatellite instability, *SD* standard deviation^a^Menopause was defined as amenorrhea for 6 months or more

Between-group comparisons of survival outcomes and identification of prognostic factors {#Sec10}
---------------------------------------------------------------------------------------

During the observation period (median, 23.9 months; range, 0.5--191.7 months), 5 patients in the amplification group and 34 in the non-amplification group died of their disease. Survival analysis indicated poorer 3-year PFS (34.4% vs. 79.9%; *P* = 0.031) and 5-year OS (25.1% vs. 84.9%; *P* = 0.014) in the amplification (vs. non-amplification) group (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Survival outcomes of patients with uterine corpus endometrial carcinoma, shown by *LYL1* gene status: **a** overall survival and (**b**) progression-free survival

*LYL1* gene amplification also showed a significant association with poor OS in univariate analysis (*P* = 0.019) (Table [2](#Tab2){ref-type="table"}). However, after adjusting for variables such as histologic type, grade, and FIGO stage, *LYL1* gene status was not confirmed as a significant prognostic factor in OS. Only advanced-stage disease (FIGO stage III-IV) emerged as an independent predictor of poor prognosis (adjusted HR, 3.509; 95% CI, 1.734--7.101; *P* \< 0.001). Table [2](#Tab2){ref-type="table"} also presents factors associated with PFS. In univariate analysis, *LYL1* gene amplification was associated with poor PFS (*P* = 0.037), but its statistical significance was not sustained in multivariate analysis. Advanced-stage disease (FIGO stage III-IV) was identified as an independent poor prognostic factor for PFS (adjusted HR, 3.581; 95% CI, 1.981--6.473; *P* \< 0.001).Table 2Factors associated with survival outcomes in patients with uterine corpus endometrial carcinomaCharacteristicsOverall survivalProgression-free survivalNUnivariate analysisMultivariate analysisNUnivariate analysisMultivariate analysisHR95% CI*P*Adjusted HR95% CI*P*HR95% CI*P*Adjusted HR95% CI*P*Age, years ≥ 631931.4560.754--2.8130.2631.2340.592--2.5700.5751571.2850.751--2.1970.3601.2240.676--2.2160.504 \< 631771 (Ref)−−1 (Ref)−−1771 (Ref)−−1 (Ref)−−Histologic type Non-endometrioid662.2321.146--4.3480.0180.8870.379--2.0740.782571.9871.112--3.5510.0201.0800.478--2.4420.853 Endometrioid3041 (Ref)−−1 (Ref)−−2771 (Ref)−−1 (Ref)−−Grade G31763.4111.661--7.0040.0012.0160.874--4.6500.1001501.5390.909--2.6070.1090.8840.453--1.7240.717 G1,21941 (Ref)−−1 (Ref)−−1841 (Ref)−−1 (Ref)−−FIGO stage III-IV894.7032.474--8.943\< 0.0013.5091.734--7.101\< 0.001723.7042.176--6.307\< 0.0013.5811.981--6.473\< 0.001 I-II2781 (Ref)−−1 (Ref)−−2591 (Ref)−−1 (Ref)−−*LYL1* amplification Yes223.0961.201--7.9820.0191.5810.541--4.6200.402182.4691.055--5.7800.0371.6520.633--4.3170.305 No3481 (Ref)−−1 (Ref)−−3161 (Ref)−−1 (Ref)−−*Abbreviations*: *HR* hazard ratio, *CI* confidence interval, *FIGO* International Federation of Gynecology and Obstetrics

We also stratified patients by tumor histologic type for subgroup analysis. In those with endometrioid cancers (*n* = 304), neither PFS (*P* = 0.070) nor OS (*P* = 0.323) differed significantly by *LYL1* gene status (amplification vs. non-amplification). However, results of multivariate analysis showed a trend towards worse PFS in the patients with *LYL1* gene amplification (adjusted HR, 4.093; 95% CI, 0.926--18.012; *P* = 0.063) (Table [3](#Tab3){ref-type="table"}).Table 3Factors associated with survival outcomes in patients with endometrioid histologic type of uterine corpus endometrial carcinomaCharacteristicsOverall survivalProgression-free survivalUnivariate analysisMultivariate analysisUnivariate analysisMultivariate analysisHR95% CI*P*Adjusted HR95% CI*P*HR95% CI*P*Adjusted HR95% CI*P*Age, years ≥ 631.7120.773--3.7900.1852.0440.887--4.7100.0931.6170.859--3.0450.1371.8530.955--3.5950.068 \< 631 (Ref)−−1 (Ref)−−1 (Ref)−−1 (Ref)−−Grade G33.0411.379--6.7040.0061.8170.768--4.3020.1741.3220.702--2.4890.3880.8890.452--1.7460.733 G1,21 (Ref)−−1 (Ref)−−1 (Ref)−−1 (Ref)−−FIGO stage III-IV4.7802.175--10.506\< 0.0014.4001.870--10.3540.0013.4021.762--6.567\< 0.0014.0492.013--8.146\< 0.001 I-II1 (Ref)−−1 (Ref)−−1 (Ref)−−1 (Ref)−−*LYL1* status Amplification2.6500.355--19.7750.3422.8230.354--22.5310.3273.4430.826--14.3470.0894.0930.926--18.1020.063 Non-amplification1 (Ref)−−1 (Ref)−−1 (Ref)−−1 (Ref)−−*Abbreviations*: *HR* hazard ratio, *CI* confidence interval, *FIGO* International Federation of Gynecology and Obstetrics

DEGs in LYL1 amplified tumors {#Sec11}
-----------------------------

We performed GSEA pathway analysis of 993 genes showing increased levels of expression in conjunction with *LYL1* amplification. Consequently, we found significant upregulation of MAPK (*P* \< 0.001), WNT (*P* = 0.002), cell cycle (*P* = 0.004), and cancer-related (*P* \< 0.001) pathways (Fig. [3a](#Fig3){ref-type="fig"}, [b](#Fig3){ref-type="fig"}). Of 993 DEGs, 384 cancer-related genes filtered via STRING database were enriched through these pathways. *MYC, CDK6, PRKACA*, and *ERBB2* genes were found to frequently interact with other cancer-related genes (Fig. [3c](#Fig3){ref-type="fig"}).Fig. 3Enrichment analysis of differentially expressed genes (DEGs), shown by *LYL1* gene status: **a** significantly enriched pathway analysis in upregulated 993 DEGs; **b** expression levels of enriched DEGs across *LYL1* amplification; and (**c**) genes in significant gene networks bearing simplified KEGG pathway annotations and grouped process-wise by commonest term prevailing in network (node size defined by degree of interaction)

We also conducted GSEA according to histologic types and TCGA classes (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Among the four TCGA classes, only the high copy number group showed *LYL1* amplifications, and cell proliferation pathway was significantly enriched in this group. Compared to endometrioid type, cancer-related and cell proliferation pathways and genes were more commonly enriched in serous type (Additional file [2](#MOESM2){ref-type="media"}: Figure S2).

Discussion {#Sec12}
==========

In the present study, we used TCGA database analysis to determine the potential impact of *LYL1* gene amplification on survival outcomes in patients with UCEC. Although patients displaying *LYL1* gene amplification showed poorer PFS and OS compared to those with non-amplification, multi-variate analyses failed to prove it as an independent prognostic factor.

A number of studies have been similarly conducted to date to identify novel biomarkers for patient survival in various types of cancer. In particular, the prognostic impact made by altered expression levels of *L1CAM* and *MYC*, both homeobox gene family members*,* has been researched through TCGA database analysis \[[@CR14]--[@CR16]\]. The *LYL1* gene, a basic helix-loop-helix transcription factor and a known oncogene in human and mouse cancers, is linked to many cancer-related properties, such as angiogenesis \[[@CR17]--[@CR19]\]. Through genetic and epigenetic modulations, the *LYL1* gene acts to regulate cell proliferation and differentiation \[[@CR8]\]. Both in vivo and in vitro experiments have also demonstrated its interactions with various oncogenes, such as *MYC, TAL1, TAL2,* and *LMO2* \[[@CR20], [@CR21]\].

Through our TCGA data analysis of *LYL1* gene amplification in patients with UCEC, we discovered that overexpressed cancer-related genes are enriched by MAPK, WNT, and cell cycle pathways in such patients. Specifically, *MYC*, *CDK6*, *PRKACA,* and *ERBB2*, all well-known oncogenes and cancer markers, were overexpressed in conjunction with *LYL1* gene amplification. Both *MYC* and *ERBB2* have likewise shown associations with uterine cancers in earlier studies \[[@CR22]--[@CR26]\]. Additionally, expression of *PRKACA* was positively correlated with *LYL1* amplification (Pearson's coefficient (r), 0.442).

Unfortunately, only advanced-stage disease emerged as a significant marker of poor prognosis in multivariate analyses. *LYL1* gene amplification was not identified as an independent prognostic factor. However, most of our cohort had early-stage disease (FIGO stages I and II: 68.6% and 6.5%, respectively). According to Surveillance, Epidemiology, and End Results data of the National Cancer Institute, the 5-year survival rate for UCEC with distant metastasis is a dismal 16.2%, compared with 95.3% for disease confined to primary sites \[[@CR27]\]. It is thus apparent that the stage of UCEC impacts survival outcomes dramatically, hindering analysis of amplification effects in the current study population.

The current study has several acknowledged limitations, the first being that associations between the *LYL1* gene and other genes or genetic mechanisms were not validated, and the proteins expressed were not measured. Such proteogenomic studies would perhaps underscore the effects of these genetic alterations and the accuracy and completeness of genomic profiling. In addition, further efforts to identify the genetic and epigenetic regulatory mechanisms of the *LYL1* gene and an evaluation of its efficacy as a prognostic indicator and therapeutic target are warranted. In UCEC cell lines, the *LYL1* gene could be overexpressed or inhibited by siRNA, determining subsequent flux in cell differentiation, proliferation, or death. A *LYL1* gene knock-out patient-derived xenograft animal model is one possible investigative approach. Another limitation was the sample size of the *LYL1* gene amplification group (*n* = 22), which was too small for reasonable statistical inferences. Despite these drawbacks, we were able to explore the prognostic potential of the novel *LYL1* gene in the setting of UCEC using both TCGA and clinicopathologic data. *LYL1* gene amplification and its association with expression levels of other genes were demonstrated as well.

Conclusions {#Sec13}
===========

In conclusion, *LYL1* gene amplification is not identified as an independent prognostic factor in UCEC. However, we discovered that cancer-related pathways, such as MAPK, WNT, and cell cycle pathways are upregulated in patients with *LYL1* amplification. Correlations between *LYL1* amplification and increased expression levels of cancer-related genes (*MYC*, *CDK*6, *PRKACA,* and *ERBB2*) are also observed. Its potential for prognostic indicator and therapeutic targeting may be implied based on overexpression of such affiliated oncogenes. Additional multi-omics and genome-wide data studies are warranted.
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Additional file 1:**Figure S1.** Gene set enrichment analysis according to histologic types and TCGA classes. (PNG 144 kb) Additional file 2:**Figure S2.** Enriched genes of cancer-related and cell proliferation pathways according to the two histologic types; serous and endometrioid. (PNG 486 kb)
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